Using gene expression profiling, we detected differential thyrotropin receptor (TSH-R) expression during human T-cell development in the thymus. This expression pattern indicated a potential role for the TSH-R within the thymus, independent of its function in the thyroid gland. Here, we demonstrate that TSH-R expression is thymus-specific within the immune system. TSH was able to bind and activate the TSH-R present on thymocytes, thereby activating calcium signaling and cyclic adenosine monophosphate signaling pathways. Mice lacking functional TSH-R expression (hyt/hyt mice) were shown to have lower frequencies of DP and SP thymocytes compared to their heterozygous littermates. Moreover, addition of TSH to co-cultures of human thymocytes enhanced T-cell development. Thus, TSH acts as a previously unrecognized growth factor for developing T cells, with potential clinical use to enhance thymic output and thereby the functional T-cell repertoire in the periphery. The direct effects of TSH on thymocytes may also explain the thus far enigmatic thymic hyperplasia in Graves' disease.
CiofaniM, Zuniga-PfluckerJC. 2007. The thymus as an inductive site for T lymphopoiesis. Annu Rev Cell Dev Biol, 23:463–493.
3.
AndersonG, JenkinsonWE, JonesT, ParnellSM, KinsellaFA, WhiteAJ, PongraćzJE, RossiSW, JenkinsonEJ. 2006. Establishment and functioning of intrathymic microenvironments. Immunol Rev, 209:10–27.
4.
TaghonT, RothenbergEV. 2008. Molecular mechanisms that control mouse and human TCR-alphabeta and TCR-gammadelta T cell development. Semin Immunopathol, 30:383–398.
5.
DikWA, Pike-OverzetK, WeerkampF, de RidderD, de HaasEF, BaertMR, van der SpekP, KosterEE, ReindersMJ, van DongenJJ, LangerakAW, StaalFJ. 2005. New insights on human T cell development by quantitative T cell receptor gene rearrangement studies and gene expression profiling. J Exp Med, 201:1715–1723.
6.
KelleyKW, WeigentDA, KooijmanR. 2007. Protein hormones and immunity. Brain Behav Immun, 21:384–392.
7.
HakimFT, CepedaR, KaimeiS, MackallCL, McAteeN, ZujewskiJ, CowanK, GressRE. 1997. Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood, 90:3789–3798.
8.
McCuneJM. 2001. The dynamics of CD4+ T-cell depletion in HIV disease. Nature, 410:974–979.
9.
DouekDC, VescioRA, BettsMR, BrenchleyJM, HillBJ, ZhangL, BerensonJR, CollinsRH, KoupRA. 2000. Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution. Lancet, 355:1875–1881.
10.
TaubDD, LongoDL. 2005. Insights into thymic aging and regeneration. Immunol Rev, 205:72–93.
11.
SocieG, StoneJV, WingardJR, WeisdorfD, Henslee-DowneyPJ, BredesonC, CahnJY, PasswegJR, RowlingsPA, SchoutenHC, KolbHJ, KleinJP. 1999. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med, 341:14–21.
12.
KingC, IlicA, KoelschK, SarvetnickN. 2004. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell, 117:265–277.
13.
WilliamsKM, HakimFT, GressRE. 2007. T cell immune reconstitution following lymphodepletion. Semin Immunol, 19:318–330.
14.
GoldbergGL, ZakrzewskiJL, PeralesMA, van den BrinkMR. 2007. Clinical strategies to enhance T cell reconstitution. Semin Immunol, 19:289–296.
SavinoW, DardenneM. 2000. Neuroendocrine control of thymus physiology. Endocr Rev, 21:412–443.
17.
DuttonCM, JobaW, SpitzwegC, HeufelderAE, BahnRS. 1997. Thyrotropin receptor expression in adrenal, kidney, and thymus. Thyroid, 7:879–884.
18.
MurakamiM, HosoiY, NegishiT, KamiyaY, MiyashitaK, YamadaM, IriuchijimaT, YokooH, YoshidaI, TsushimaY, MoriM. 1996. Thymic hyperplasia in patients with Graves' disease. Identification of thyrotropin receptors in human thymus. J Clin Invest, 98:2228–2234.
19.
MurakamiM, HosoiY, ArakiO, MorimuraT, ImamuraM, OgiwaraT, MizumaH, MoriM. 2001. Expression of thyrotropin receptors in rat thymus. Life Sci, 68:2781–2787.
20.
BagriacikEU, KleinJR. 2000. The thyrotropin (thyroid-stimulating hormone) receptor is expressed on murine dendritic cells and on a subset of CD45RBhigh lymph node T cells: functional role for thyroid-stimulating hormone during immune activation. J Immunol, 164:6158–6165.
21.
ChabaudO, LissitzkyS. 1977. Thyrotropin-specific binding to human peripheral blood monocytes and polymorphonuclear leukocytes. Mol Cell Endocrinol, 7:79–87.
22.
WortsmanJ, McConnachieP, BakerJRJr, BurmanKD. 1988. Immunoglobulins that cause thymocyte proliferation from a patient with Graves' disease and an enlarged thymus. Am J Med, 85:117–121.
23.
GunnA, MichieW, IrvineWJ. 1964. The thymus in thyroid disease. Lancet, 2:776–778.
24.
CostagliolaS, SwillensS, NiccoliP, DumontJE, VassartG, LudgateM. 1992. Binding assay for thyrotropin receptor autoantibodies using the recombinant receptor protein. J Clin Endocrinol Metab, 75:1540–1544.
25.
TaghonT, Van de WalleI, De SmetG, De SmedtM, LeclercqG, VandekerckhoveB, PlumJ. 2009. Notch signaling is required for proliferation but not for differentiation at a well-defined beta-selection checkpoint during human T-cell development. Blood, 113:3254–3263.
26.
SchmittTM, Zuniga-PfluckerJC. 2002. Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro. Immunity, 17:749–756.
27.
StaalFJ, WeerkampF, LangerakAW, HendriksRW, CleversHC. 2001. Transcriptional control of T lymphocyte differentiation. Stem Cells, 19:165–179.
28.
van DongenJJ, LangerakAW, BruggemannM, EvansPA, HummelM, LavenderFL, DelabesseE, DaviF, SchuuringE, Garcia-SanzR, van KriekenJH, DroeseJ, GonzalezD, BastardC, WhiteHE, SpaargarenM, GonzalezM, ParreiraA, SmithJL, MorganGJ, KnebaM, MacintyreEA. 2003. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia, 17:2257–2317.
29.
BeillardE, PallisgaardN, van der VeldenVH, BiW, DeeR, van der SchootE, DelabesseE, MacintyreE, GottardiE, SaglioG, WatzingerF, LionT, van DongenJJ, HoklandP, GabertJ. 2003. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)—a Europe against cancer program. Leukemia, 17:2474–2486.
30.
van den BergHR, KhanNA, van der ZeeM, BonthuisF, JNIJ, DikWA, de BruinRW, BennerR. 2009. Synthetic oligopeptides related to the [beta]-subunit of human chorionic gonadotropin attenuate inflammation and liver damage after (trauma) hemorrhagic shock and resuscitation. Shock, 31:285–291.
31.
Visser-WisselaarHA, Van UffelenCJ, Van KoetsveldPM, Lichtenauer-KaligisEG, WaaijersAM, UitterlindenP, MooyDM, LambertsSW, HoflandLJ. 1997. 17-beta-estradiol-dependent regulation of somatostatin receptor subtype expression in the 7315b prolactin secreting rat pituitary tumor in vitro and in vivo. Endocrinology, 138:1180–1189.
32.
van ZelmMC, ReisliI, van der BurgM, CastanoD, van NoeselCJ, van TolMJ, WoellnerC, GrimbacherB, PatinoPJ, van DongenJJ, FrancoJL. 2006. An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med, 354:1901–1912.
33.
Pike-OverzetK, de RidderD, WeerkampF, BaertMR, VerstegenMM, BrugmanMH, HoweSJ, ReindersMJ, ThrasherAJ, WagemakerG, van DongenJJ, StaalFJ. 2007. Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy. Leukemia, 21:754–763.
34.
LuisTC, WeerkampF, NaberBA, BaertMR, de HaasEF, NikolicT, HeuvelmansS, De KrijgerRR, van DongenJJ, StaalFJ. 2009. Wnt3a deficiency irreversibly impairs hematopoietic stem cell self-renewal and leads to defects in progenitor cell differentiation. Blood, 113:546–554.
35.
HershmanJM. 2004. Physiological and pathological aspects of the effect of human chorionic gonadotropin on the thyroid. Best Pract Res Clin Endocrinol Metab, 18:249–265.
36.
NakabayashiK, MatsumiH, BhallaA, BaeJ, MosselmanS, HsuSY, HsuehAJ. 2002. Thyrostimulin, a heterodimer of two new human glycoprotein hormone subunits, activates the thyroid-stimulating hormone receptor. J Clin Invest, 109:1445–1452.
37.
Powell-JonesCH, ThomasCGJr, NayfehSN. 1980. Thyrotropin receptors in normal human thyroid. Nonclassical binding kinetics not explained by the negative cooperativity model. J Biol Chem, 255:4001–4010.
38.
LatifR, MorshedSA, ZaidiM, DaviesTF. 2009. The thyroid-stimulating hormone receptor: impact of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on multimerization, cleavage, and signaling. Endocrinol Metab Clin North Am, 38:319–341, viii.
39.
SteinSA, OatesEL, HallCR, GrumblesRM, FernandezLM, TaylorNA, PuettD, JinS. 1994. Identification of a point mutation in the thyrotropin receptor of the hyt/hyt hypothyroid mouse. Mol Endocrinol, 8:129–138.
40.
de PooterR, Zuniga-PfluckerJC. 2007. T-cell potential and development in vitro: the OP9-DL1 approach. Curr Opin Immunol, 19:163–168.
SoriskyA, AntunesTT, GagnonA. 2008. The Adipocyte as a novel TSH target. Mini Rev Med Chem, 8:91–96.
43.
ZhangW, TianLM, HanY, MaHY, WangLC, GuoJ, GaoL, ZhaoJJ. 2009. Presence of thyrotropin receptor in hepatocytes: not a case of illegitimate transcription. J Cell Mol Med, 13:4636–4642.
44.
AbeE, MariansRC, YuW, WuXB, AndoT, LiY, IqbalJ, EldeiryL, RajendrenG, BlairHC, DaviesTF, ZaidiM. 2003. TSH is a negative regulator of skeletal remodeling. Cell, 115:151–162.
45.
WangJ, WhetsellM, KleinJR. 1997. Local hormone networks and intestinal T cell homeostasis. Science, 275:1937–1939.
46.
SpitzwegC, JobaW, HeufelderAE. 1999. Expression of thyroid-related genes in human thymus. Thyroid, 9:133–141.
47.
ColobranR, Armengol MdelP, FanerR, GartnerM, TykocinskiLO, LucasA, RuizM, JuanM, KyewskiB, Pujol-BorrellR. 2011. Association of an SNP with intrathymic transcription of TSHR and Graves' disease: a role for defective thymic tolerance. Hum Mol Genet, 20:3415–3423.
48.
JiangS, ChowSC, NicoteraP, OrreniusS. 1994. Intracellular Ca2+ signals activate apoptosis in thymocytes: studies using the Ca(2+)-ATPase inhibitor thapsigargin. Exp Cell Res, 212:84–92.
49.
CarletonM, HaksMC, SmeeleSA, JonesA, BelkowskiSM, BergerMA, LinsleyP, KruisbeekAM, WiestDL. 2002. Early growth response transcription factors are required for development of CD4(−)CD8(−) thymocytes to the CD4(+)CD8(+) stage. J Immunol, 168:1649–1658.
50.
AifantisI, GounariF, ScorranoL, BorowskiC, von BoehmerH. 2001. Constitutive pre-TCR signaling promotes differentiation through Ca2+ mobilization and activation of NF-kappaB and NFAT. Nat Immunol, 2:403–409.
51.
GuptaA, TerhorstC. 1994. CD3 delta enhancer. CREB interferes with the function of a murine CD3-delta A binding factor (M delta AF). J Immunol, 152:3895–3903.
52.
GottschalkLR, LeidenJM. 1990. Identification and functional characterization of the human T-cell receptor beta gene transcriptional enhancer: common nuclear proteins interact with the transcriptional regulatory elements of the T-cell receptor alpha and beta genes. Mol Cell Biol, 10:5486–5495.
53.
GradyGC, MasonSM, StephenJ, Zuniga-PfluckerJC, MichieAM. 2004. Cyclic adenosine 5′-monophosphate response element binding protein plays a central role in mediating proliferation and differentiation downstream of the pre-TCR complex in developing thymocytes. J Immunol, 173:1802–1810.
54.
WangJ, KleinJR. 1996. Hormone regulation of murine T cells: potent tissue-specific immunosuppressive effects of thyroxine targeted to gut T cells. Int Immunol, 8:231–235.
